EU Medicine Authorizations 2025: A Milestone fo...

By HEOR Staff Writer

January 20, 2026

EU Medicine Authorizations 2025: A Year of Innovation Advancements in EU Medicine Authorizations for 2025 In 2025, the European Medicines Agency (EMA) r...
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications